Get the content you want anytime you want.

Top 5 Contagion® News Articles for the Week of October 1, 2017

The following is a snapshot of our top 5 infectious disease articles from this past week:

#5: How to Improve Fungal Disease Management Worldwide

In an article published in The Lancet Infectious Diseases, Donald C. Cole, FRCP, from the University of Toronto, Ontario, Canada, and colleagues describe the current state of identification and management of fungal diseases and discuss potential approaches for improving their recognition and treatment.

According to the authors, estimates of the burden of fungal diseases in low-income and middle-income countries made by the Global Action Fund for Fungal Infections (GAFFI) exceed the capability of these countries to manage the burden.

To read more about improving fungal disease management, click here.

#4: Maraviroc-Containing PrEP Regimens Found to be Safe in Women

HIV infections continue to occur at a rate of >2 million globally each year with women accounting for a little over 50% of infections. Although the overall incidence of HIV infections in the United States has decreased in recent years, certain populations remain particularly vulnerable, including racial/ethnic minorities, adolescents/young adults, and people in the southern United States. Antiretroviral therapy has been highly successful in reducing AIDS outcomes and death in HIV-infected patients worldwide; however, transmission of HIV remains a major global health problem.

The approval of oral TDF-FTC for HIV pre-exposure prophylaxis (PrEP) represents an approved intervention to help control this epidemic; however, the tolerability of this regime and the subsequent discontinuation of therapy pose a threat to the efficacy, and therefore, the main purpose of this management approach. Maraviroc (MVC), a CCR5 antagonist HIV entry inhibitor, has been approved for treatment of HIV infection treatment-experienced participants and has many attributes that make it a viable candidate for HIV PrEP in women. Regimens containing MVC have been studied in terms of safety and tolerability in HIV uninfected men and transgender women who undertake risky sexual activity or with unknown sero-status men. The results of these studies showed the regimen to be largely well-tolerated with 84% of the participants completing the 48-week study. Notably, the reasons for discontinuation were similar across the regimens.

Read more about Maraviroc-containing PrEP regimens, here

Big advances in treatment can